Bioartificial Organ Market Size, Share and Trend Analysis, By Organ Type (Bioartifical Kidney, Liver, Heart, Lung, Pancreas, and Others), By Cell Type (Autologous Cells, Allogenic Cells, Xenogeneic Cells, Stem Cells), By Material Type, By Application, By End-Use, and By Region, Forecast 2025-2032

Bioartificial Organ Market Overview and Key Insights:

The global bioartificial organ market size reached USD 26.3 Million in 2024 and is expected to register a revenue CAGR of 19.6% during the forecast period. Rising prevalence of chronic organ failure diseases is a major factor driving revenue growth of the global bioartificial organ market.

Globally, mortality rates for chronic kidney disease (CKD), acute kidney injury (AKI), liver failure, and heart disease are increasing exponentially, which results in generating demand for bioartificial organs. According to the International Society of Nephrology (ISN), around 850 million people worldwide are suffering some form of kidney disease.

The adoption of bioartificial kidneys is rising rapidly among patients as traditional organ transplantation faces challenges such as organ donor shortages, long waiting lists, and transplant rejection risks. According to the National Kidney Foundation, over 2 million people rely on dialysis or kidney transplants to survive.

Market Drivers:

Shortage of donor organs for organ transplantation is further contributing to revenue growth of the market. This shortage is evident, owing to limited donor availability, organ rejection risks, and post-transplant complications. According to the Health Resources and Services Administration (HRSA) of the U.S. Department of Health, currently 103,223 patients including men, women, and children on the transplant waiting list, and 17 people die each day while waiting for organ transplantation.

Rising usage of bioengineered cardiac patches made from bioartificial tissues is significantly accelerating the revenue growth of the bioartificial organ market. Bioartificial tissues are suitable in the treatment of post-myocardial infarction (MI) cardiac repair, owing to their regenerative properties and ability to restore cardiac function. Globally, cardiovascular disease (CVD) is rising at a rapid rate which is supporting market growth rate. According to the World Health Organization (WHO), CVDs account for 17.9 million deaths annually.

Market Opportunity:

Increasing geriatric population is a significant growth opportunity for bioartificial organ market. According to the World Health Organization (WHO), by 2030, 1 in 6 people will be aged 60 years or over, and by 2050, 80% of older adults will reside in low- and middle-income countries. Older individuals are more susceptible to organ failure, which results in generation of substantial opportunities to meet the growing demand for bioartificial organs that can address shortages in organ donation.

Moreover, the rising prevalence of Cystic Fibrosis (CF) is expected to fuel the market revenue growth over the forecast period. The Cystic Fibrosis Foundation reports that there are nearly 40,000 people with CF in the United States, with an estimated 105,000 diagnosed globally. Cystic Fibrosis (CF) characterized by chronic bacterial infection leads to pulmonary dysfunction and progressive structural lung damage. Bioartificial organs can aid in managing the disease.

Recent Trends:

Advancement in 3D & 4D bioprinting and tissue engineering are emerging as a key industry trend in bioartificial organ market. Three-dimensional (3D) organ bioprinting utilizes additive manufacturing (AM) technologies to layer cells, stem cells, growth factors, and other biomaterials to construct bioartificial organs that closely mimic natural tissue and organ structures. This new innovation enables the creation of organs with customized geometrical shapes, physiological functions, and biomaterial constituents based on patient-specific data such as CT and MRI scans.

3D bioprinting offers new possibilities for customized implants and tissue regeneration. Tissue engineering and bioartificial tissue generation are creating therapeutic approaches to replacing damaged organs. Tissue engineering is capable of addressing critical organ shortages and improving treatment of diseases such as chronic lung conditions, heart failure, and liver disease. Moreover, human bio-artificial muscle (BAM), scaffold geometry, and biomaterial selection in 3D bioprinting are driving innovations in the market.

Restraints & Challenges:

High manufacturing costs are a major factor hindering the revenue growth of bioartificial organ market. The cost of manufacturing owing to high cost of research and development (R&D) bioartificial organs is limiting its widespread adoption, particularly among patients facing financial burdens. These costs are further impacting the overall expenses associated with transplantation procedure. For example, the UK National Health Service (NHS) reported that the costs of treating three patients with stem cell-based tissue-engineered tracheas ranged from USD 174,420 to USD 740,500.

According to the International Society of Nephrology (ISN), between 5.3 and 10.5 million people globally require dialysis or organ transplants. Majority of patients cannot afford these treatments due to financial barriers and uncertain insurance coverage. Moreover, commercialization of bioartificial organs involves rigorous regulatory requirements and extensive clinical trials by the U.S. Food and Drug Administration and the European Medicines Agency (EMA). Delays in the approval process and regulatory clearances can slow down product commercialization, which may affect market revenue growth.

Organ Type Segment Insights and Analysis:

Based on the organ type, the bioartificial organ market is segmented into bioartificial kidney, liver, heart, lung, pancreas, and others.

Bioartifical kidney contributed the largest revenue share in 2024. Increasing incidence of kidney disease is a key contributor to revenue share growth of this market. Chronic kidney disease, along with acute renal failure (ARF), is becoming a significant concern, with mortality rates from ARF among ICU patients exceeding. According to the National Kidney Foundation, 10% of the global population is affected by CKD, with millions dying annually due to a lack of access to affordable treatment.

Bioartifical liver segment is expected to register the fastest revenue growth over the forecast period. Rising incidence of liver diseases such as cirrhosis, hepatitis, and liver failure are expected to accelerate market revenue growth. Advancements in liver tissue engineering are emerging owing to their ability to differentiate into functional liver cells.

Application Segment Insights and Analysis:

Based on the application, the bioartificial organ market is segmented into organ transplantation, tissue regeneration & repair, drug discovery and testing, and others.

Organ transplantation segment contributed the largest revenue share in 2024. The global demand for organ transplants continues to grow significantly with the shortages of traditional organ transplantation globally. Bioartificial organ is a promising alternative to address the critical shortage of organs. Furthermore, technological advancements in bioengineering and 3D bioprinting are enhancing the demand for bioartificial organs and improving the success rates of organ transplantation.

Tissue regeneration & repair segment is expected to register fastest revenue growth over the forecast period. Advancements in regenerative medicine, tissue engineering, and 3D bioprinting are expected to accelerate market revenue growth over the forecast period. Regenerative medicine is the field of medicine and biology responsible for the regeneration of tissues or organs. Tissue engineering and 3D bioprinting help in regenerating tissues with complex geometries. These advancements are generating significant opportunities in the treatment of chronic diseases such as heart disease, kidney failure, and liver injury.

Geographical Outlook:

Bioartificial Organ Market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Bioartificial Organ Market :

North America registered highest market share in the bioartificial organ market. Rapid funding and grants in advanced product development in organ bioengineering a major revenue share contributors in this region. Government Institutions and organizations are providing significant funding to support the ongoing development of transplantable bioartificial hearts.

For instance, on August 2023, the Texas Heart Institute was recently awarded a five-year, USD 2 million grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to enhance technology for the development of transplantable bioartificial hearts.

Shortages of organ donors and long waiting lists for kidney and liver transplants are further driving revenue growth, particularly in the United States. According to the Health Resources and Services Administration of the U.S., in 2024, approximately 89,792 patients are waiting for a kidney transplant, while 9,424 patients are awaiting a liver transplant.

Additionally, increasing prevalence of chronic diseases is expected to accelerate market revenue expansion in this region over the forecast period. For instance, according to a study by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health & Human Services, approximately 129 million people in the U.S. have at least one major chronic disease, such as heart disease, cancer, diabetes, obesity, or hypertension.

Asia-Pacific Bioartificial Organ Market :

Asia Pacific is expected to register fastest revenue growth by 2032. Rising prevalence of chronic kidney disease (CKD) is driving revenue growth in this region. Bioartificial Organs are highly adopted in the treatment of chronic kidney disease (CKD) owing to rising shortages in kidney transplantation. According to an estimate by The Korean Society of Nephrology, around 434 million people across Eastern, Southern, and Southeastern Asia are affected by chronic kidney disease (CKD), with approximately 65 million in stages 4–5.

The shortage of organ donations is significantly driving revenue growth in countries like Japan and India. According to the Japan Organ Transplant Network, approximately 16,000 individuals are currently on the transplant waiting list. India faces a high burden of chronic diseases, including diabetes and hypertension, further increasing the demand for organ transplantation. According to the National Institutes of Health (NIH), the current annual transplant rate of 11,243 kidneys falls far short of the estimated 200,000 renal failure cases each year.

Europe Bioartificial Organ Market :

Europe contributed a substantial revenue share in 2024. Rising geriatric population in this region are expected to drive the market revenue growth over the forecast period. According to the European Union (EU), as of January 1, 2023, the EU population was estimated to be 448.8 million, with over one-fifth (21.3%) of the population aged 65 years and older. The older population is at a higher risk for chronic diseases, and transplantation shortages are increasing across the region. As a result, the demand for bioartificial organs is expected to grow over the projected period.

Moreover, funding for healthcare research and innovations is also expected to fuel the market revenue growth. The European Union (EU) is investing in various healthcare research programs aimed at reducing the risks of chronic diseases among its citizens. As of December 2022, Horizon Europe, the primary EU funding program for research and innovation, has an overall budget of USD 101.23 billion USD, with USD 8.74 billion USD specifically allocated to health research. ​

Competition Analysis:

The bioartificial organ market is characterized by a consolidated structure, with major players competing across various segments and regions. The list of major players included in the bioartificial organ market report are:

• United Therapeutics Corporation
• Miromatrix Medical Inc.
• IVIVA Medical, Inc.
• Organovo Holdings, Inc.
• Humacyte Global, Inc.
• Athersys, Inc.
• Organogenesis Inc.
• XenoTherapeutics Foundation
• BioLife Solutions Inc.
• Pandorum International Inc.

Strategic Developments in Bioartificial organ market:

• On 24^th April 2024, United Therapeutics Corporation successfully performed the world’s first transplant of a UThymoKidney. This groundbreaking procedure is the first-ever xenothymokidney transplant into a living person, and the first-ever combined mechanical heart pump and organ transplant. The transplant received authorization from the U.S. Food and Drug Administration (FDA).
• On 13^th June 2023, IVIVA Medical, a biotechnology startup focused on developing living therapeutics to treat organ failure, received the award for its innovative work in developing a fully implantable bioartificial kidney using 3D printing technology. As part of the prize, IVIVA will receive USD 1 million to further advance its research and create cell-based living therapeutics that replicate the essential functions of the kidney.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights of The Bioartificial organ market Report:

The bioartificial organ market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Organ Type Outlook (Revenue, USD Million; 2022-2032)
  • Bioartifical Kidney
  • Bioartifical Liver
  • Bioartifical Heart
  • Bioartifical Lung
  • Bioartifical Pancreas
  • Others

• Cell Type Outlook (Revenue, USD Million; 2022-2032)
  • Autologous Cells
  • Allogenic Cells
  • Xenogeneic Cells
  • Stem Cells

• Material Type Outlook (Revenue, USD Million; 2022-2032)
  • Synthetic Polymers
    • Polylactic Acid (PLA)
    • Polyglycolic Acid (PGA)
    • Polycaprolactone (PCL)
    • Polyethylene Glycol (PEG)
    • Others
  • Natural Polymers
    • Collagen
    • Fibrin
    • Chitosan
    • Alginate
  • Carbohydrates
    • Hyaluronic Acid
    • Dextran
    • Agarose
  • Decellularized Natural Tissues
  • Others

• Application Outlook (Revenue, USD Million; 2022-2032)
  • Organ Transplantation
  • Tissue Regeneration & Repair
  • Drug Discovery and Testing
  • Others

• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Hospitals & Transplant Centers
  • Biotechnology & Biopharmaceutical Companies
  • Research Institutes & Academic Laboratories

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) About the Bioartificial Organ Market Report